Preventive Strategies to Reduce Sarcopenia Risk During GLP-1-Based Anti-Obesity Therapy
Journal of Clinical Medicine · 27.07.2026 · 15 (15) · 5870
DOI: 10.3390/jcm15155870 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 27.07.2026. Verfasst von Andrej Belančić und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 119 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and related incretin-based therapies are highly effective anti-obesity treatments, but weight loss may also include reductions in fat-free mass, raising concern for selected patients at risk of sarcopenia. This narrative review summarizes current evidence and practical, evidence-informed strategies to support muscle health during GLP-1 RA-based anti-obesity therapy. Particular emphasis is placed on identifying higher-risk patients, including older adults, frail individuals, patients with low baseline muscle mass or strength, sarcopenic obesity, chronic kidney disease, low physical activity, or rapid weight loss. Preventive strategies include baseline assessment of body composition and muscle function, individualized resistance and multicomponent exercise, adequate protein intake, attention to nutritional adequacy, and periodic monitoring of body composition, strength, and physical performance. Treatment pace and dose escalation may also be individualized in higher-risk patients when unfavorable changes in fat-free mass or function occur. Current evidence remains limited, and many recommendations are extrapolated from weight-loss, nutrition, exercise, and sarcopenia literature rather than GLP-1 RA-specific trials. Overall, a risk-stratified and multidisciplinary approach may help preserve muscle mass and function while maintaining the cardiometabolic benefits of GLP-1 RA-based therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Basic and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia.
- Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia.
- Hospital for Medical Rehabilitation of Heart and Lung Diseases and Rheumatism Thalassotherapia-Opatija, 51410 Opatija, Croatia.
- Independent Researcher, 11741 Athens, Greece.
- Department of Social Medicine and Epidemiology, Faculty of Medicine, University of Rijeka, 51000 Rijeka, Croatia.
- School of Nursing and Health Sciences, Hong Kong Metropolitan University, Hong Kong, China.
ORCID-Profile: Andrej Belančić, Kristina Skroče, Elvira Meni Maria Gkrinia, Man Ki Kwok
Zitieren
APA
Belančić, A., Skroče, K., Gkrinia, E. M. M., Marinović Glavić, M., & Kwok, M. K. (2026). Preventive Strategies to Reduce Sarcopenia Risk During GLP-1-Based Anti-Obesity Therapy. Journal of Clinical Medicine, 15(15), 5870. https://doi.org/10.3390/jcm15155870
Vancouver
Belančić A, Skroče K, Gkrinia EMM, Marinović Glavić M, Kwok MK. Preventive Strategies to Reduce Sarcopenia Risk During GLP-1-Based Anti-Obesity Therapy. Journal of Clinical Medicine. 2026;15(15):5870. doi:10.3390/jcm15155870
BibTeX
@article{Belani2026,
author = {Belančić, Andrej and Skroče, Kristina and Gkrinia, Elvira Meni Maria and Marinović Glavić, Mihaela and Kwok, Man Ki},
title = {Preventive Strategies to Reduce Sarcopenia Risk During GLP-1-Based Anti-Obesity Therapy},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {15},
pages = {5870},
doi = {10.3390/jcm15155870}
}
EUVIMED